Standard Contracts
Underwriting AgreementUnderwriting Agreement • May 14th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
Contract Type FiledMay 14th, 2018 Company Industry JurisdictionKiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [—] Class A common shares (the “Firm Shares”) and, at the election of the Underwriters, up to [—] additional Class A common shares (the “Optional Shares”) of the Company (such Class A common shares of the Company being referred to herein as the “Common Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are collectively called the “Shares”.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 14th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • Massachusetts
Contract Type FiledMay 14th, 2018 Company Industry JurisdictionThis Amended and Restated Employment Agreement (this “Agreement”) is made and entered into as of , 2018 (the “Effective Date”), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the “Company”), and Rasmus Holm-Jorgensen (the “Employee”).
Confidential Treatment Requested by Kiniksa Pharmaceuticals, Ltd. LICENSE AGREEMENT between MEDIMMUNE, LIMITED and KINIKSA PHARMACEUTICALS, LTD.License Agreement • May 14th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations
Contract Type FiledMay 14th, 2018 Company IndustryThis License Agreement (the “Agreement”) is made and entered into effective as of December 21, 2017 (the “Effective Date”) by and between MedImmune, Limited, a limited liability company duly authorized and existing under the laws of England and Wales (“MedImmune”) and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (“Licensee”). MedImmune and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ASSET PURCHASE AGREEMENT between KINIKSA PHARMACEUTICALS, LTD. and BIOGEN MA INC. dated as of September 7, 2016 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been...Asset Purchase Agreement • May 14th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
Contract Type FiledMay 14th, 2018 Company Industry JurisdictionThis Asset Purchase Agreement (this “Agreement”) is made and entered into as of September 7, 2016 (the “Effective Date”), between Biogen MA Inc., a Massachusetts corporation (“Biogen”), and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (“Kiniksa”). Kiniksa and Biogen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 14th, 2018 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • Massachusetts
Contract Type FiledMay 14th, 2018 Company Industry JurisdictionThis Amended and Restated Employment Agreement (this “Agreement”) is made and entered into as of May , 2018 (the “Effective Date”), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the “Company”), and Sanj K. Patel (the “Executive”).